Skip to main content

6 Result(s)

within P. G. Cassell Remove this filter Medicine & Public Health Remove this filter

and

  1. Article

    Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in women of European and Asian origin

    Aims/hypothesis. Uncoupling proteins are mitochondrial transmembrane carriers implicated in the regulation of energy balance. Dysfunction of UCP3 (the predominant uncoupling protein in skeletal m...

    P. G. Cassell, P. J. Saker, S. J. Huxtable, E. Kousta, A. E. Jackson… in Diabetologia (2000)

    Download PDF (86 KB)

  2. Article

    35th Annual Meeting of the European Association for the Study of Diabetes

    A. Melander, J. Olsson, G. Lindberg, A. Salzman, T. Howard, P. Stang… in Diabetologia (1999)

    Download PDF (43004 KB)

  3. Article

    An uncoupling protein 2 gene variant is associated with a raised body mass index but not Type II diabetes

    Aims/hypothesis. Linkage between markers close to the uncoupling protein 2 and 3 genes (11q13) and resting metabolic rate and a pre-diabetic phenotype have been found. The syntenic region in mous...

    P. G. Cassell, M. Neverova, S. Janmohamed, N. Uwakwe, A. Qureshi… in Diabetologia (1999)

    Download PDF (67 KB)

  4. No Access

    Chapter and Conference Paper

    Primary Malignant Lymphoma of the Rectum Associated with Chronic Ulcerative Colitis

    Adenocarcinoma of the large bowel is well established as an important complication of chronic ulcerative colitis. The cumulative risk in patients with 25 years’ history of extensive colitis is about 9% [1]. Ho...

    A. L. Desai, P. G. Cassell in Updates in Colo-Proctology (1992)

  5. No Access

    Article

    Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer

    M. L. Slevin, V. J. Harvey, P. F. M. Wrigley… in Cancer Chemotherapy and Pharmacology (1983)

  6. No Access

    Article

    Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer

    One hundred and seventy six patients (81 controls, 95 receiving treatment) have entered a prospective randomized tiral of long-term oral adjuvant razoxane (ICRF-159) following removal of a colorectal cancer. T...

    J. M. Gilbert, K. Hellmann, M. Evans, P. G. Cassell… in Cancer Chemotherapy and Pharmacology (1982)